45results about How to "Less adverse effect" patented technology

A virtual machine management apparatus connected to a plurality of server devices via a network generates a new virtual machine on a server device in accordance with a request from a management terminal. At that time, for one or more server devices to which a new virtual machine can be allocated, the virtual machine management apparatus refers to an allocation rule table for storing a score for each of combinations of types of virtual machines. The score indicates appropriateness of a condition that each combination of types of virtual machines is to be allocated to the same server device. Thus, the virtual machine management apparatus computes an index value indicative of appropriateness of a condition that the new virtual machine is to be allocated to the server device. Then the virtual machine management apparatus determines an allocation target for the new virtual machine with reference to the computed index value.

The invention concerns novel pharmaceutical compositions and methods for the treatment of allergic rhinitis. More specifically, the invention concerns the inhibition of histamines, which is one of the primary causes of allergic rhinitis in human patients. The inventive pharmaceutical compositions include a carbonyl group-containing moiety, optionally in acidic medium, that combines with histamine to block histamine activity and thus reduce undesirable physiological effects of histamine in the body.

The presently-disclosed subject matter includes biodegradable scaffolds. Exemplary biodegradable scaffolds comprise a plurality of polythioketal polymers, and a plurality of polyisocyanates, where at least one polyisocyanate is linked to at least one polymer to form the scaffold. Thus, certain embodiments of scaffolds comprise a cross-linked network of the polythioketal polymers and the polyisocyanates. The presently-disclosed subject matter also includes methods for treating tissue, such as skin or bone tissue, in a subject in need thereof. Treatment methods comprise contacting the tissue with an effective amount of the biodegradable scaffold. Furthermore, the presently-disclosed subject matter includes methods for making the present biodegradable scaffolds.

A near-infrared absorptive liquid dispersion, which contains a near-infrared absorptive compound represented by formula (1) that is dispersed in a form of fine particles in a dispersing medium:

wherein R^1a and R^1b may be the same or different, and each independently represent an alkyl group, an aryl group, or a heteroaryl group; R² and R³ each independently represent a hydrogen atom or a substituent, and at least one of R² and R³ is an electron withdrawing group; R² may be bonded to R³ to form a ring; and R⁴ represents a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a substituted boron, or a metal atom, and R⁴ may be covalently bonded or coordinately bonded to at least one among R^1a, R^1b and R³.

It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpynrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of Tween-20; 0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a a high concentration on skin, a deep anesthetic effect and a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics.

Various embodiments of the present invention are directed toward a method for preparing probiotic nanoparticles from natural sources, comprising performing a biological preparation phase such as isolating any cells derived from either prokaryote or eukaryote cells, performing a chemical preparation phase such as performing an enzymatic procedure (or heating, or chemicals) for killing or obtaining cell derived ingredients, performing a physical preparation phase such as performing ultrasonication, and performing a formulation preparation phase such as powderized drying.

According to the present invention, a powdery preparation for nasal administration comprising a physiologically active substance, a non-water-absorbing and hardly water-soluble powder(s) and one or two selected from the group consisting of a mucolytic agent and a nonionic surfactant is provided.

A photo-curable resin composition includes a photo-acid generator, a dye having an absorption in a range of 760 to 2,000 nm, and a cationic photopolymerizable composition, wherein the photo-acid generator generates an acid by irradiation of near-infrared light to initiate cationic polymerization reaction for curing. Alternatively, a photo-curable resin composition includes a radical generator, a dye having an absorption in a range of 760 to 2,000 nm, and a radical photopolymerizable composition, wherein radical polymerization reaction is initiated by irradiation of near-infrared light to perform curing.

A light source device according to one of the invention comprises a light emitting element; a light guide substrate into which light emitted from the light emitting element enters; a mounting substrate on which the light emitting element is mounted; and a conductive pattern for removing a static electricity in or on the light guide substrate, formed on the mounting substrate.

The present invention relates to micellar nanocomplexes and a method of forming the same. The micellar nanocomplex comprises a micelle and an agent encapsulated within said micelle, where the micelle comprises a polymer-flavonoid conjugate, wherein said polymer is bonded to the B ring of said flavonoid. The micellar nanocomplex may have useful applications as a drug-delivery system.

A pharmaceutical composition for treatment of nephritis of the present invention comprises a triprenylphenol compound as an active substance, preferably the triprenylphenol compound represented by the following general formula (1) as an active substance, and further preferably orniplabin represented as n=3 in the following general formula (1) as an active substance.

general formula (1) (in formula (1) n is one of integer selected from 1 to 10).

Further a manufacturing method of a pharmaceutical composition for treatment or prevention of nephritis of the present invention comprises using a triprenylphenol compound as an active substance.

The present invention pertains to humanized anti-EGFR antibodies having antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. In particular, the present invention is directed to humanized anti-EGFR antibodies which are useful in the treatment of cancer.

This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R¹ and R² are independently of each other hydrogen atom, C_1-6alkyl group or C_6-14aryl group, R³ is hydrogen atom or C_1-6alkylcarbonyloxy group, or together with R⁴ forms a bond, R⁴ is hydrogen atom, or together with R³ forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR⁷R⁸, NR⁹, O, S, SO or SO₂, R⁵ is hydrogen atom or C_1-6alkyl group, R⁶ is hydrogen atom, C_1-6alkyl group, C_3-8cycloalkyl group, C_3-8cycloalkenyl group, amino group, C_1-6alkylamino group, di-C_1-6alkylamino group, C_6-14arylamino group, C_2-9heteroarylamino group, C_6-14aryl group, C_2-9heteroaryl group or C_2-9heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.

PCT No. PCT/JP97/04306 Sec. 371 Date Jun. 2, 1999 Sec. 102(e) Date Jun. 2, 1999 PCT Filed Nov. 26, 1997 PCT Pub. No. WO98/24431 PCT Pub. Date Jun. 11, 1998Novel N-substituted pyrrolidine derivatives having a highly selective and potent antagonism against smooth muscle muscarine receptors and being useful for the treatment of irritable bowel syndrome and the like, characterized by being represented by general formula (1) wherein R represents a hydrogen atom, a halogen atom, or a lower alkoxy group and a process for preparing the same.

A method for supporting a user, a corresponding computer program product, a corresponding data medium, and a corresponding imaging system are provided. According to the method, a three-dimensional (3D) data set depicting a target object is provided, and at least one two-dimensional (2D) image of the target object is automatically acquired. The 2D image and the 3D data set are automatically registered with each other by a 2D/3D registration. A spatial direction in which the 2D/3D registration exhibits greatest uncertainty is automatically specified. A signal for aligning an instrument that is provided for the purpose of examining the target object is then automatically generated and output as a function of the specified spatial direction in order to support the user.

The present invention relates to a method of treating MS in a human patient in need of such treatment and comprises administering to said patient a combination therapy in a single oral dosage form (e.g. a tablet or capsule) of dim ethyifurrta rate and one agent selected from teriflunomide (or its prodrug leflunomide), fingolimod and laquinimod. This combination is more effective than the single agents alone and/or has reduced side effects and better tolerability than the single agents alone and/or can be given in a reduced frequency. Moreover, the present invention is directed to a pharmaceutical composition suitable for the oral treatment of multiple sclerosis consisting of dimethylfumarate and one agent selected from teriflunomide, fingolimod and laquinimod as active ingredients and one or more pharmaceutically acceptable excipients.

The present invention relates to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs, more particularly; to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs in postmenopausal women comprising one or more of Platycodi Radix and Cynanchum wilfordii extract and/or Phlomis umbrosa extract. The present invention provides a composition, a pharmaceutical composition and a food composition capable of replacing estrogen, which comprise one or more selected from the group consisting of Platycodi Radix extract and Cynanchum wilfordii extract and/or Phlomis umbrosa extract. The composition of this invention comprised of the extracts of natural source shows little or no adverse effects such as cancer occurrence compared with estrogen-replacing agent used for conventional hormone replacement therapy; in addition, it has excellent effect on the regeneration and proliferation of tissue cells of female sexual organs, so that it is applicable to treatment of various disorders and diseases developed in postmenopausal women who are deficient in estrogen. Moreover, the composition of this invention has little impurities and high amount of active ingredients.

The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.

A face mask has an ultraviolet (UV) light-emitting diode (LED) mounted in a respiration tube that extends through an outer shell of the mask. A power source is connected to the UV LED. The respiration tube is serpentine in shape so as to maximize the amount time the air is subjected to the UV radiation. The movement of the air as well as additional heat sinks in the tube reduce the amount of heat radiating from the LEDs during use. This arrangement protects the user and others from excessive UV exposure and heat during use.

To develop a compound which is highly accumulated in cancer cells and capable of emitting an α-ray and provide a pharmaceutical composition for cancer treatment including the compound.

A pharmaceutical composition for cancer treatment including a compound having a structure in which ²¹¹At is introduced as a substituent into an amino acid derivative having an affinity with an amino acid transporter LAT1 or a pharmaceutically acceptable salt of the compound.

The present invention relates to Suprabioavailable oral composition of Pirfenidone or salt thereof when compared with reference product of Pirfenidone capsule [267 mg] and tablet [267 mg and 801 mg] for the treatment of idiopathic pulmonary fibrosis (IPF). The Suprabioavailable oral composition of Pirfenidone or salt thereof provides at least 5% dose reduction which minimizes adverse effects and provides more efficacy with better patient compliance in the treatment of idiopathic pulmonary fibrosis.

The present invention relates to a novel compound isolated from Quamoclit sp., and more particularly to a novel compound isolated from Quamoclit sp. and a composition for preventing or treating diabetes and its complications comprising the compound as an active ingredient. The novel compound isolated from Quamoclit sp. according to the present invention has excellent effects on lowering blood sugar, promoting insulin secretion, inhibiting VEGF expression, and so on. Thus, the present invention not only functions to prevent or treat diabetes and its complications, but also functions to promote treatment effects when treated together with conventional diabetes medicines.